Jennifer Knight, MD, MS, FACLP

Associate Professor, Psychiatry and Behavioral Medicine and Microbiology & Immunology

Locations

Psychiatry and Behavioral Medicine

Contact Information

Biography

Dr. Knight completed her undergraduate training at the University of Wisconsin-Madison and her medical training at the Medical College of Wisconsin. She completed her residency training in a combined Internal Medicine and Psychiatry program at Rush University in Chicago, and is double board certified in both specialties. She also completed a post-doctoral research fellowship in psychoneuroimmunology at the University of Rochester Medical Center.

Research Interests

Dr. Knight’s research interests involve investigating the physiologic and immunologic effects that account for the relationship between psychosocial factors and clinical outcomes in hematopoietic stem cell transplant recipients. Clinically, she is the Medical Director of the Psycho-Oncology Program at Froedtert and MCW and specializes in general and psycho-oncology psychosomatic medicine consultation. She sees patients at the MCW Cancer Center and at Froedtert Hospital. She is on faculty at the Neuroscience Research Center and is also a Clinical Member of the MCW Cancer Center in the Transplantation Biology and Immunotherapy Research Program.

Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A Center for International Blood and Marrow Transplant Research Analysis.

(Paulson K, Brazauskas R, Khera N, He N, Majhail N, Akpek G, Aljurf M, Buchbinder D, Burns L, Beattie S, Freytes C, Garcia A, Gajewski J, Hahn T, Knight J, LeMaistre C, Lazarus H, Szwajcer D, Seftel M, Wirk B, Wood W, Saber W.) Biol Blood Marrow Transplant. 2019 Oct;25(10):2086-2090.
Toxicities of CAR T-Cell Therapy and the Role of the Consultation-Liaison Psychiatrist.

(Pawar DS, Molinaro JR, Knight JM, Heinrich TW.) Psychosomatics. 2019 Sep - Oct;60(5):519-523.
Proinflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes.

(Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Yingst A, Couriel D, Alousi A, Pidala J, Knight JM, Verneris MR.) Biol Blood Marrow Transplant. 2019 01;25(1):12-18.
Interleukin (IL)-6: A good kid hanging out with bad friends (and why sauna is good for health).

(Raison CL, Knight JM, Pariante C.) Brain Behav Immun. 2018 10;73:1-2.
Increasing provider awareness of and recommendations for yoga and meditation classes for cancer patients.

(Koula MJ, Knight JM.) Support Care Cancer. 2018 Oct;26(10):3635-3640.
Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis.

(Wood WA, Brazauskas R, Hu ZH, Abdel-Azim H, Ahmed IA, Aljurf M, Badawy S, Beitinjaneh A, George B, Buchbinder D, Cerny J, Dedeken L, Diaz MA, Freytes CO, Ganguly S, Gergis U, Almaguer DG, Gupta A, Hale G, Hashmi SK, Inamoto Y, Kamble RT, Adekola K, Kindwall-Keller T, Knight J, Kumar L, Kuwatsuka Y, Law J, Lazarus HM, LeMaistre C, Olsson RF, Pulsipher MA, Savani BN, Schultz KR, Saad AA, Seftel M, Seo S, Shea TC, Steinberg A, Sullivan K, Szwajcer D, Wirk B, Yared J, Yong A, Dalal J, Hahn T, Khera N, Bonfim C, Atsuta Y, Saber W.) Biol Blood Marrow Transplant. 2018 09;24(9):1928-1935.
Prevalence of self-reported sleep dysfunction before allogeneic hematopoietic cell transplantation.

(D'Souza A, Millard H, Knight J, Brazauskas R, Lee SJ, Flynn KE, Rizzo JD, Shaw BE.) Bone Marrow Transplant. 2018 08;53(8):1079-1082.
Severity, course, and predictors of sleep disruption following hematopoietic cell transplantation: a secondary data analysis from the BMT CTN 0902 trial.

(Jim HSL, Sutton S, Majhail NS, Wood WA, Jacobsen PB, Wingard JR, Wu J, Knight JM, Syrjala KL, Lee SJ.) Bone Marrow Transplant. 2018 08;53(8):1038-1043.
Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation.

(Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Ahmed I, Beitinjaneh A, Buchbinder D, Byrne M, Callander N, Chao N, Choi SW, DeFilipp Z, Gadalla SM, Gale RP, Gergis U, Hashmi S, Hematti P, Holmberg L, Inamoto Y, Kamble RT, Lehmann L, MacMillan MA, McIver Z, Nishihori T, Norkin M, O'Brien T, Olsson RF, Reshef R, Saad A, Savani BN, Schouten HC, Seo S, Solh M, Verdonck L, Vij R, Wirk B, Yared J, Horowitz MM, Knight JM, Verneris MR.) Bone Marrow Transplant. 2018 07;53(7):932-937.
Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation.

(Knight JM, Kerswill SA, Hari P, Cole SW, Logan BR, D'Souza A, Shah NN, Horowitz MM, Stolley MR, Sloan EK, Giles KE, Costanzo ES, Hamadani M, Chhabra S, Dhakal B, Rizzo JD.) BMC Cancer. 2018 May 24;18(1):593.
Host interleukin 6 production regulates inflammation but not tryptophan metabolism in the brain during murine GVHD.

(Belle L, Zhou V, Stuhr KL, Beatka M, Siebers EM, Knight JM, Lawlor MW, Weaver C, Hashizume M, Hillard CJ, Drobyski WR.) JCI Insight. 2017 Jul 20;2(14).
Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.

(El-Jawahri A, Chen YB, Brazauskas R, He N, Lee SJ, Knight JM, Majhail N, Buchbinder D, Schears RM, Wirk BM, Wood WA, Ahmed I, Aljurf M, Szer J, Beattie SM, Battiwalla M, Dandoy C, Diaz MA, D'Souza A, Freytes CO, Gajewski J, Gergis U, Hashmi SK, Jakubowski A, Kamble RT, Kindwall-Keller T, Lazarus HM, Malone AK, Marks DI, Meehan K, Savani BN, Olsson RF, Rizzieri D, Steinberg A, Speckhart D, Szwajcer D, Schoemans H, Seo S, Ustun C, Atsuta Y, Dalal J, Sales-Bonfim C, Khera N, Hahn T, Saber W.) Cancer. 2017 05 15;123(10):1828-1838.

Jennifer Knight, MD, MS, FACLP